NuGen Announces Completion of InsuJet(TM) Training with Sol-Millennium(TM) Brazil
NuGen Medical Devices has announced the successful completion of sales and clinical training for its needle-free device, InsuJet, with Sol-Millennium Medical in Brazil. This marks a key step for introducing InsuJet into the Brazilian market, a significant growth target given its population of over 200 million. The training, completed on June 26, 2024, follows recent purchase orders for Canada and Europe, underscoring NuGen's expanding global footprint. CEO Ian Heynen anticipates imminent purchase orders, highlighting the importance of this development in NuGen's South American strategy.
- Completion of sales and clinical training for InsuJet in Brazil.
- Brazil as a major market with over 200 million people.
- Imminent purchase orders expected for InsuJet in Brazil.
- Recent purchase orders placed for Canada and Europe.
- None.
Toronto, Ontario--(Newsfile Corp. - July 1, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that as of June 26, 2024, the commercial teams of Sol-MillenniumTM Medical Inc. ("Sol-MTM") in Brazil have successfully completed the sales and in-depth clinical training required for InsuJetTM's launch in the Brazilian market. This is the next step in the rollout plan for Sol-MTM as a key InsuJetTM distributor, building on NuGen's June 21, 2024, announcement of Sol-MTM purchase orders placed for customer demand in Canada and Europe.
With a population of over 200 million, Brazil is a major South American market and a key growth target for NuGen. The InsuJetTM has regulatory approval for sale in Brazil and training the Sol-MTM team enables the launch into this large and important market.
NuGen's CEO Ian Heynen commented "The training of the commercial teams at Sol-MTM Brazil is another significant step forward in our global rollout plan. Sol-MTM's teams are now poised to develop the InsuJetTM in NuGen's largest addressable market in South America[1] and we expect to see purchase orders in the near future."
About NuGen:
NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously.
The Company is marketing and selling its next-generation InsuJet™ needle-free injection system designed to improve the lives of millions of diabetics.
InsuJet™ is approved for sale in 42 countries around the world.
About Sol-MillenniumTM:
Sol-MTM is one of the world's largest manufacturers of needles and syringes. It is vertically integrated with locations across the globe. Sol-MTM's innovative technology helps positive patient outcomes, saves on medication, and enhances both clinician and patient experience. With an international sales team dedicated to delivering knowledge and outstanding customer service, Sol-MTM's goal is to partner with those in healthcare, focusing on a healthier tomorrow.
For further information, please visit:
Websites: www.insujet.com, www.nugenmd.com and www.solm.com/insujet/
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/ and www.linkedin.com/company/sol-millennium-medical-group/
For further information, please contact:
Tony Di Benedetto
Executive Chairman
(416) 791-9399
tony@nugenmd.com
Ian Heynen
CEO
(416) 560-1019
ian@nugenmd.com
To arrange a media interview with NuGen, please contact:
Morna Gorman
(416) 553-1732
morna@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
[1] Source: Population by Country (2023) - Worldometer (worldometers.info), Countries ranked by Diabetes prevalence (% of population ages 20 to 79) (indexmundi.com) and Estimate-of-Insulin-Use-in-Type-2-Diabetes.pdf (haiweb.org).
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/214948
FAQ
What did NuGen Medical Devices announce on July 1, 2024?
What is the significance of the InsuJet training completion in Brazil for NuGen Medical Devices?
What are the anticipated next steps for InsuJet in Brazil after the training completion?
What recent developments support NuGen's expansion of InsuJet in South America?
